Eton Pharmaceuticals (ETON) Stock Price, News & Analysis

Company Overview

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for underserved patient populations, with an emphasis on pediatric, rare disease and other difficult-to-treat conditions. The company generally pursues products with established clinical or regulatory pathways and works to bring them to market through its own commercial operations or strategic partnerships.

Eton’s marketed portfolio includes Eprontia, an oral solution formulation of topiramate used in the treatment of certain seizure disorders; Biorphen, an injectable phenylephrine product used to treat clinically important low blood pressure; and Alkindi Sprinkle, a hydrocortisone granule product for replacement therapy in children with adrenal insufficiency. The company also maintains a pipeline of development and product-acquisition opportunities in specialty and orphan pharmaceuticals.

Founded in 2017, Eton is headquartered in Deer Park, Illinois, and primarily serves the U.S. pharmaceutical market. The company is led by Sean Brynjelsen, who serves as president and chief executive officer.

Key Stats

• Today's Range: $55.41 to $57.50
• 50-Day Range: $37.19 to $64.43
• 52-Week Range: $14.27 to $66.37
• Volume: 891,649 shs
• Average Volume: 465,441 shs
• Market Capitalization: $1.59 billion
• P/E Ratio: 146.05
• Dividend Yield: N/A
• Price Target: $67.50
• Consensus Rating: Moderate Buy

Eton Pharmaceuticals Stock Analysis - MarketRank™

Eton Pharmaceuticals scored higher than 91% of companies evaluated by MarketBeat, and ranked 31st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eton Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Eton Pharmaceuticals has a consensus price target of $67.50, representing about 21.6% upside from its current price of $55.50.

Amount of Analyst Coverage

Eton Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 71.68%

Earnings Growth

Earnings for Eton Pharmaceuticals are expected to grow by 71.68% in the coming year, from $1.13 to $1.94 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eton Pharmaceuticals is 146.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eton Pharmaceuticals is 146.05, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.49.

Price to Book Value per Share Ratio

Eton Pharmaceuticals has a P/B Ratio of 56.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.65% of the float of Eton Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eton Pharmaceuticals has a short interest ratio ("days to cover") of 1.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eton Pharmaceuticals has recently decreased by 5.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eton Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eton Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.31

News Sentiment

Eton Pharmaceuticals has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Eton Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 15 people have searched for ETON on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

5 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Eton Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,580,250.00 in company stock.

Percentage Held by Insiders

16.49% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

27.86% of the stock of Eton Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ETON
• CIK: 1710340
• Web: www.etonpharma.com
• Phone: (847) 787-7361
• Fax: N/A
• Employees: 44
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Eton Pharmaceuticals: $67.50
• High Price Target: $70.00
• Low Price Target: $62.00
• Potential Upside/Downside: +21.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.38
• Trailing P/E Ratio: 146.05
• Forward P/E Ratio: 49.12
• P/E Growth: N/A
• Net Income: -$4.60 million
• Net Margins: 12.02%
• Pretax Margin: 12.07%
• Return on Equity: 40.13%
• Return on Assets: 12.37%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 1.52
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: $79.95 million
• Price / Sales: 19.84
• Cash Flow: $0.01 per share
• Price / Cash Flow: 10,707.67
• Book Value: $0.98 per share
• Price / Book: 56.63

Miscellaneous

• Outstanding Shares: 28,580,000
• Free Float: 23,870,000
• Market Cap: $1.59 billion
• Optionable: Optionable
• Beta: 0.90